Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
about
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialA systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Drug resistance and the role of combination chemotherapy in improving patient outcomes.An update on chemotherapy and tumor gene expression profiles in breast cancer.
P2860
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@en
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@nl
type
label
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@en
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@nl
prefLabel
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@en
Gene expression profiling of b ...... icrotubule-stabilizing agents.
@nl
P2093
P2860
P1476
Gene expression profiling of b ...... microtubule-stabilizing agents
@en
P2093
Anthony Gonçalves
Daniel Birnbaum
François Bertucci
Gais Kadra
Pascal Finetti
Yves Toiron
P2860
P2888
P304
P356
10.1007/S10549-011-1687-8
P407
P577
2011-07-27T00:00:00Z